{"filings":[{"id":1231357,"accession_number":"0001437749-26-021495","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2026-06-24T11:00:25+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Autonomix Medical announces 1-for-21 reverse stock split effective June 24, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share count reduces from 11.4M to ~543,000; authorized shares remain at 500M.","No fractional shares; cash paid in lieu based on 5-day VWAP before split.","Exercise prices and share counts for options/warrants adjusted proportionally.","New CUSIP 05330T304; ticker AMIX unchanged.","Post-split net loss per share for FY2026 recalculated to ($48.80) from ($2.32)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106254,"accession_number":"0001437749-26-001381","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Autonomix Medical receives Nasdaq bid price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 14, 2026: bid price below $1.00 for 30 consecutive business days.","Initial 180-day compliance period ends July 13, 2026; need $1.00 close for 10 consecutive days.","If non-compliant by July 13, may get second 180-day period if meets other listing standards.","Company may consider a reverse stock split to regain compliance with Bid Price Rule.","No guarantee of regaining compliance; delisting possible if not cured or appeal fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106253,"accession_number":"0001437749-26-000937","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autonomix reports pancreatic cancer pain relief across all stages in PoC study at ASCO GI 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rapid pain reduction within 24 hours of transvascular RF denervation procedure.","At 7 days, 93.75% of responding patients (N=16) improved from severe to mild/moderate pain.","At 4-6 weeks, ~2/3 of responders (N=9) maintained mild or eliminated pain levels.","At 3 months, no responders (N=6) had severe pain; 50% maintained mild or eliminated pain.","Even late-stage (Stage 4) patients showed meaningful early improvement despite disease progression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122557,"accession_number":"0001437749-25-035733","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Autonomix Medical raises $5.0M via private placement of pre-funded and Series C warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$5.0M from sale of pre-funded warrants (4,501,666 shares at $0.001) and Series C warrants (9,003,332 shares at $0.8607).","Combined purchase price per unit $1.110; warrants immediately exercisable; Common Warrants expire in 5.5 years.","Placement agent Maxim Group LLC receives 8% fee plus up to $50k expenses.","Net proceeds for working capital and general corporate purposes; registration statement for resale to be filed within 20 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122556,"accession_number":"0001437749-25-032798","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Autonomix Medical stockholders approve reverse split, expanded equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; Forvis Mazars ratified as auditor for FY ending Mar 2026.","Reverse stock split authorized at ratio of 1-for-2 to 1-for-25, board discretion for one year.","Amended and restated 2023 Equity Incentive Plan approved, increasing authorized shares by 1.9M to ~2.27M.","Issuance of >20% of outstanding common stock to Lincoln Park Capital Fund, LLC approved.","Total shares voted 2,871,639 (48% of outstanding) constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139249,"accession_number":"0001437749-25-027890","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Autonomix Medical increases ATM equity offering by $1.4M to $3.5M aggregate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased at-market issuance sales agreement with Ladenburg Thalmann by $1.4 million; total shares may now be sold up to $3.5 million aggregate price.","Sales made under effective shelf registration statement on Form S-3 (File No. 333-285464), effective March 11, 2025.","No other events disclosed; proceeds intended for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139248,"accession_number":"0001437749-25-027719","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Autonomix Medical enters $15M equity purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lincoln Park committed to purchase up to $15M in common stock over 24 months at Company's discretion.","Company issued 261,932 commitment shares to Lincoln Park as upfront consideration.","Purchase price is 97% of lower of daily low or avg of 3 lowest closing prices over prior 10 days.","Company may direct Regular Purchases of 30,000-75,000 shares, capped at $500k per purchase.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139247,"accession_number":"0001437749-25-023246","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Autonomix Medical raises $2.5M via warrant exercise inducement, issues new Series B warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant exercise price reduced to $1.723/share; holders exercise/prepay for 1,477,596 shares.","Gross proceeds ~$2.5M before fees; placement agent Ladenburg Thalmann receives 8% cash fee.","New Series B warrants for 1,477,596 shares at $1.723, 5.5-year term, immediately exercisable.","Company will file resale registration statement for new warrant shares by Aug 20, 2025.","Post-transaction common shares outstanding: 4,877,625."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156808,"accession_number":"0001437749-25-013631","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autonomix PoC1 trial meets objectives; initiates PoC2 expansion study for visceral cancer pain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 20 patients enrolled; 19 treated via transvascular RF ablation; 84% femoral-access responders achieved 53.3% mean VAS pain reduction at 7 days.","100% of responding patients zero opioid use at 7 days post-procedure; 73% remained opioid-free at 4-6 weeks follow-up.","No device- or procedure-related serious adverse events; 6 subjects died from disease progression unrelated to the procedure.","PoC2 phase begins Q2 2025, targeting additional visceral cancers (liver, gall bladder, bile duct) and earlier-stage pancreatic cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175215,"accession_number":"0001437749-25-005739","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Autonomix Medical enters $2.1M ATM equity facility; reverse split share dispute","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM sales agreement with Ladenburg Thalmann for up to $2.1M of common stock; 3.0% agent commission.","Proceeds from ATM to be used for working capital and general corporate purposes.","October 2024 1-for-20 reverse split reduced shares from ~23M to ~1.15M; authorized shares remain 500M.","DTCC requested 271,846 shares for fractional rounding; company disputes and has not issued; potential liability.","Retrospective restatement of per-share data in 10-K to reflect reverse split; no new financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175214,"accession_number":"0001437749-25-003673","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Autonomix Medical reports Q3 FY2025 net loss of $2.7M, cash $11.8M; PoC trial data on track for 1H2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.7M for Q3 ended Dec 31, 2024 vs $3.1M a year ago; nine-month net loss $8.2M vs $10.0M.","Cash position $11.8M as of Dec 31, 2024; raised $10M in underwritten public offering during the quarter.","Topline proof-of-concept trial data for pancreatic cancer pain expected in 1H2025; US clinical trials targeted for 2H2025.","Achieved design lock for RF ablation catheter after successful animal testing; expanded IP with new U.S. patent grant.","Targeting De Novo submission in 2026 and potential FDA clearance for pancreatic cancer pain in 2027."],"consensus_eps_estimate":-1.1271,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175213,"accession_number":"0001437749-25-001558","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autonomix Medical CEO presents at Virtual Investor Closing Bell; no new material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Brad Hauser participated in the Virtual Investor Closing Bell Series on January 22, 2025.","Presentation was furnished as Exhibit 99.1 but is an image file; no specific figures or financial data extracted.","Replay available on company website for 90 days; forward-looking statements with risks noted.","No guidance changes, financial results, or operational updates were included in the text filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192157,"accession_number":"0001437749-24-036182","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Autonomix Medical raises $10.0M in underwritten public offering of common and pre-funded units","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10.0M from 615,500 common units (incl. 156,809 over-allotment) and 917,596 pre-funded units.","Price per common unit $6.54; per pre-funded unit $6.539; each includes a Series A warrant exercisable at $6.54 for 5 years.","Underwriters partially exercised over-allotment for 156,809 shares and Series A warrants.","Net proceeds to fund clinical trial, R&D, IP development, and working capital.","Ladenburg Thalmann sole bookrunner; offering closed Nov 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192156,"accession_number":"0001437749-24-034326","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Autonomix Q2 FY2025 net loss $2.8M; PoC trial shows 100% of lead-in patients off opioids at 4-6 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.8M for three months ended Sept 30, 2024 vs $6.0M loss same quarter last year; cash $5.2M.","100% of lead-in responders zero opioid use at 4-6 weeks post-procedure; 83% pain reduction at follow-up.","60% enrollment reached in pancreatic cancer pain PoC trial; 79% responder rate with zero opioid use at 7 days.","Upcoming milestones: complete enrollment Q4 CY2024, topline data 1H 2025, FDA clearance targeted 1H 2027.","R&D expense $1.2M (vs $0.5M YoY) driven by clinical trial and product development costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192155,"accession_number":"0001437749-24-033163","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Autonomix Medical disputes DTCC demand for 271,846 shares after reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed 1-for-20 reverse stock split on Oct 24, 2024; no fractional shares, rounding to full share.","DTCC on Nov 1, 2024 requested 271,846 shares for street-name holder rounding.","Company disputes count based on ~4,800 record holders; launched inquiry, will not issue shares pending.","Potential liability exists if company is ultimately required to issue the requested shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192154,"accession_number":"0001437749-24-032175","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Autonomix Medical to effect 1-for-20 reverse stock split effective Oct 24, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split ratio range 1:2 to 1:50; board selected 1:20.","Reverse split effective 11:59 pm ET Oct 24, 2024; Nasdaq trading post-split begins Oct 25 under AMIX.","Outstanding shares reduce from ~23.0 million to ~1.15 million; authorized shares remain 500 million.","No fractional shares issued; holders of fractional shares will receive rounding up to nearest whole share.","Proportionate adjustments to exercise prices and shares for options, warrants, and convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192153,"accession_number":"0001437749-24-031491","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Autonomix shareholders approve reverse stock split authorization up to 1:50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to authorize reverse stock split (ratio 1:2 to 1:50) passed with 13.4M for, 3.8M against, 104.7K abstain.","All five director nominees elected: Klemp, Bisson, Foster, Robbins, Capelli each received >14.1M votes for.","Ratification of Forvis Mazars as independent auditor approved with 16.9M for, 89.6K against, 313.8K abstain.","Annual meeting held October 17, 2024; 17.35M shares voted (75.3% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208639,"accession_number":"0001437749-24-029752","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Autonomix Medical receives Nasdaq bid price deficiency notice; 180 days to regain $1.00 minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Sept. 16, 2024, for bid price below $1.00 for 30 consecutive business days.","Compliance deadline is March 17, 2025; must close at $1.00 or more for at least 10 consecutive days.","If not compliant by March 17, may qualify for second 180-day period if it meets other listing standards.","Company may consider a reverse stock split to cure the deficiency; no guarantee of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208638,"accession_number":"0001437749-24-026162","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Autonomix Medical reports Q1 FY2025 net loss $2.7M, positive 7-day pain relief data from lead-in patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.7M vs $0.9M YoY; cash $6.8M as of June 30, 2024.","G&A $1.8M (up $1.3M) and R&D $1.0M (up $0.6M) driven by compensation and clinical costs.","60% of first five lead-in patients had mean 6.33 VAS pain reduction (from 8.0 to 1.67) at 7 days.","Appointed Brad Hauser CEO; licensed RF Innovations' FDA-cleared Apex 6 ablation generator.","Expects topline PoC trial data 1H CY2025, FDA de novo submission 2026, clearance 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208637,"accession_number":"0001437749-24-022711","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Autonomix licenses FDA-cleared ablation technology; issues 250,000 shares to RF Innovations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensed intellectual property for Apex 6 Radiofrequency Generator, an FDA-cleared ablation device for peripheral nerve pain.","Consideration is 250,000 shares of common stock; license is perpetual, non-exclusive, worldwide, and royalty-free.","Transaction expected to close before the end of July 2024; manufacturing partner to be integrated into supply chain.","Technology supports Autonomix's development for pancreatic cancer pain and other indications, potentially simplifying regulatory pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226364,"accession_number":"0001437749-24-021003","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Autonomix Medical adjusts executive salaries, approves cash bonuses and option grants for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Salary changes: Executive Chair Klemp decreased to $150k; CFO Smith increased to $285k; CTO Toth decreased to $137.5k.","Cash bonuses for FY2024: CEO Bisson $150k; CFO Smith $74.25k; CMO Schwartz $35k.","Option grants at $1.3280 ex. price, 10-yr term, 4-yr vest: Bisson 377,221; Klemp 175,452; Smith 228,087; Schwartz 263,178; Toth 175,452.","All actions approved by Compensation Committee on June 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226363,"accession_number":"0001437749-24-020591","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autonomix reports positive preliminary PoC trial results in pancreatic cancer pain patients; 60% responders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60% of lead-in patients responded with mean 6.33 VAS pain reduction (8.0 to 1.67) at 7 days post-procedure.","No procedural complications or significant adverse events in the first five patients.","Responders reported 78% improvement in quality of health and 45% improvement in quality of life at 7 days.","Femoral access patients responded; brachial access did not; trial enrollment on track for year-end 2024.","Pain relief as quick as 1 day post-procedure; two patients succumbed to disease (expected, unrelated)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226362,"accession_number":"0001437749-24-020534","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["3.02","5.02","7.01","9.01"],"status":"ready","headline":"Autonomix names Brad Hauser CEO; grants 900k-share inducement option; Bisson becomes Vice Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Hauser appointed CEO and President; base salary $450,000, target bonus 60%.","Hauser receives 10-year option for 900,000 shares at closing price on June 17, vesting over 4 years.","Lori Bisson steps down as CEO, appointed Executive Vice Chair and Strategic Adviser; base salary $150,000, target bonus 50%.","Bisson continues vesting in prior options and forfeits severance in connection with the role change.","Inducement options granted outside 2023 Stock Plan per Nasdaq Listing Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226361,"accession_number":"0001437749-24-018924","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Autonomix Medical FY2024 net loss $15.4M; cash $8.6M; topline data from first 5 patients expected June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.4M vs $2.0M prior year, including $8.0M non-cash warrant loss; G&A $5.2M, R&D $2.2M.","Cash $8.6M at March 31, 2024; expects runway into Q1 2025 after $9.8M net IPO proceeds.","IPO raised $11.2M gross ($9.8M net) via 2,234,222 shares at $5.00 each.","PoC human clinical study for pancreatic cancer pain ongoing; topline data from first 5 patients expected in June 2024.","Preclinical study showed statistically significant reduction in metastases and tumor mass with targeted nerve ablation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245389,"accession_number":"0001683168-24-001265","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autonomix Medical CEO presents at Virtual Investor event; no financial details disclosed in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Lori Bisson participated in 'Virtual Investor What This Means Segment' on Feb 29, 2024.","Presentation attached as Exhibit 99.1 but full content not provided in the filing excerpt.","No specific financial or operational updates are extractable from the given text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245388,"accession_number":"0001683168-24-000570","cik":1617867,"company_name":"Autonomix Medical, Inc.","ticker":"AMIX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["3.02","8.01","7.01","9.01"],"status":"ready","headline":"Autonomix Medical closes $11.2M IPO, regains cardiology rights via $8M warrant deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed Jan 26: 2,234,222 shares at $5.00, gross proceeds $11,171,110 before expenses.","Regained exclusive worldwide cardiology rights from Impulse Medical in exchange for warrant to buy 1.6M shares at $0.001 per share.","CEO Lori Bisson cites momentum and on-track first-in-human pancreatic cancer pain study this quarter.","Warrant shares subject to lockup: 12.5% for 6 months, remainder for 12 months post-IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4378004.718399617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}